Navigation Links
Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
Date:2/20/2013

LA JOLLA, Calif., Feb. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported its financial results for the fourth quarter and year-ended December 31, 2012 and recent company highlights.

"In 2012, we successfully achieved significant strategic and financial objectives that have enabled Regulus to become a publicly-traded biopharmaceutical company. In particular, we successfully completed our initial public offering, formed alliances with new partners and expanded existing relationships with our pre-existing partners.  Our strategic relationships provide therapeutic expertise that will support our growing microRNA therapeutic platform," said Kleanthis G. Xanthopoulos , Ph.D., President and CEO of Regulus.  "With our solid strategic foundation in place, we are now focused on building a meaningful clinical portfolio.  We continue to advance our partnered and proprietary programs toward the clinic and look forward to nominating our first microRNA candidate for clinical development in the first half of this year." 

"Regulus continues to maintain a strong balance sheet, ending 2012 with greater than $98 million in cash," said Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President of Finance. "Our solid financial position should enable us to operate into 2016 and execute on our current research and development objectives."

Fourth Quarter 2012 and Recent Corporate Highlights

  • Presented Positive Preclinical Data on miR-21 at Kidney Week 2012.
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
    2. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
    3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
    4. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
    5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    7. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
    8. Regulus Appoints Mark G. Foletta to its Board of Directors
    9. Regulus to Present at Two Upcoming Investor Conferences
    10. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  GlySens ... two-year, two million dollar grant from the National Institute ... division of the National Institutes of Health (NIH).  The ... the GlySens second generation ICGM™ long term implantable glucose ... are underway, and enrollment is expected to begin before ...
    (Date:11/24/2014)... DEVON, England , Nov. 24, 2014 /PRNewswire/ ... https://www.facebook.com/PifflersUnited announced the release of results ... pain therapy device, in the self-management of fibromyalgia ... the area of worst pain, very significant clinically ... The 140 group members with fibromyalgia used ...
    (Date:11/23/2014)... Nov. 23, 2014  Aurobindo Pharma USA ... Capsules, USP 300 mg 100-count bottles to the consumer ... some empty capsules. Empty capsules could result ... consequences that could range from no effect, short term ... epilepticus (long period seizures) that could be life-threatening. Aurobindo ...
    Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
    ... SB-509 to be Evaluated in Repeat-Dosing Study in Subjects ... Inc. (Nasdaq: SGMO ) announced today that it ... its drug, SB-509, in subjects,with ALS, a progressive, degenerative ... no cure., Sangamo,s drug, SB-509, is an injectable ...
    ... MIAMI and PALM BEACH, Fla., Sept. 2 ... of Miami and,Palm Beach announce a revolutionary new way ... of radiation. Prostate cancer is,the most common form of ... CEO, James G. Schwade, M.D., says, "for many cases,that ...
    Cached Medicine Technology:Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
    (Date:11/24/2014)... Philadelphia, PA (PRWEB) November 24, 2014 ... care coordination and disease management services to health ... to implement Essette’s Medical Management software suite. ... SaaS platform in a program to reduce patients' ... includes Population Health Management, Care Management, Utilization Management, ...
    (Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
    (Date:11/23/2014)... Tbdress.com has recently announced that ... Nov. 28, 2014. The special offer will provide ladies many ... one of the world’s largest women’s dresses retailers, and its ... can enjoy great discounts on that day: Everything at Tbdress.com ... (for orders above $89). , People can use the following ...
    (Date:11/23/2014)... 23, 2014 (HealthDay News) -- The holidays can be ... sensory overload can trigger major meltdowns, an expert says. ... best of circumstances, but when you have children with ... an occupational therapy professor at University of the Sciences ... "It,s best to let your hosts or visitors know ...
    (Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are popular ... its new collection of power suppliers. Additionally, it has ... suppliers. All the new models come with big discounts, ... Dec. 20, 2014. , SWAccessControl.com has thousands of happy ... for a long time. It is very wise to ...
    Breaking Medicine News(10 mins):Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
    ... Technology Company Provides Interoperable ... CARROLLTON, Ga., July 9 Greenway Medical ... Week,s Capitol Hill,Technology Showcase, held in Washington D.C. ... one of the healthcare IT industry,s first and ...
    ... Summer, LAUREL, Miss., July 9 With the kids ... TV-watchers, Sanderson Farms,introduces the kick ,em off the couch for ... food and becoming more active., Studies show that over ... than they do in school or participating in any activity ...
    ... by the Wellcome Trust have identified a key mechanism that ... of blood vessels and avoid being destroyed by the body,s ... Cell , highlights an important potential new target for anti-malarial ... killing over a million people every year, mainly children and ...
    ... they believe to be the most accurate way of predicting ... obese mothers, according to a study in the UK-based journal ... the University of Rochester Strong Memorial Hospital in Rochester, New ... out of ten cases using the gestation-adjusted projection method (GAP). ...
    ... finds more than 350 common sets of genes in patients ... activity in breast cancer cells from younger patients could explain ... a younger age. , "We haven,t had a good reason ... study author Dr. Kimberly Blackwell, director of the clinical trials ...
    ... Laboratories,Inc. (Nasdaq: MLAB ) announced today that it ... annual list of the 100 fastest-growing,publicly held small companies ... public companies with annual revenues of less than $200 ... share, revenues, and stock,performance over the past three years. ...
    Cached Medicine News:Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 2Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 3Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 4Health News:Sanderson Farms Launches New Summer Program Encouraging Families to Get Healthy 2Health News:Discovery of key malaria proteins could mean sticky end for parasite 2Health News:Research highlights problems of predicting birthweights in obese mothers 2Health News:Research highlights problems of predicting birthweights in obese mothers 3Health News:Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 2Health News:Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 3Health News:Mesa Laboratories, Inc. Named to Fortune Small Business Magazine's 2008 List 2
    ... and O.R. staff work hard to protect ... intravasation. Manual methods are complicated, time-consuming, and ... II Fluid Management System for hysteroscopy, designed ... irrigation. It has been developed to provide ...
    ... These precision 4mL PYREX ... calibrated "To Contain" (TC - ... (TD - top line) to ... ware. Pipets are color-coded with ...
    1000L...
    ... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
    Medicine Products: